NCT06781983 - Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

January 24, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2029

Conditions

Advanced or Metastatic Solid Tumors

Interventions

DRUG

IPH4502

Part 1 (dose escalation) and Part 2 (dose optimization)

Trial Locations (7)

RECRUITING

Mount Sinai Tisch Cancer Center, New York

RECRUITING

NEXT Oncology - Virginia, Fairfax

RECRUITING

Centre Léon Bérard, Lyon

RECRUITING

NEXT Oncology - Dallas, Dallas

RECRUITING

Gustave Roussy Cancer Institute, Villejuif

RECRUITING

Massachusetts General Hospital - Boston, Boston

RECRUITING

John Theurer Cancer Center, Hackensack